The effect of methylxanthine, corticosteroid, and N -acetylcystein on plasma oxidant/antioxidant levels in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 215s Year: 2001
Increased leukotriene and lower prostaglandin E2 concentrations in induced sputum of patients with eosinophilic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 733s Year: 2005
Thromboxane B2 (TXB2) urine levels during long term treatment with montelukast (M) in asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 353s Year: 2001
Plasma vitamin D concentration and clinical characteristics in clinically stable patients with moderate COPD Source: Annual Congress 2011 - Physiological basis of respiratory disease Year: 2011
Prostaglandin D2 metabolite as a marker of asthma exacerbations Source: Eur Respir J 2002; 20: Suppl. 38, 424s Year: 2002
Aspirin significantly decreases urinary leukotriene E4 concentration in aspirin-tolerant asthma patients who show hyperleukotrienuria in stable condition Source: Annual Congress 2007 - New mechanisms in the pathogenesis of asthma and allergy Year: 2007
Inhaled substance P, but not neurokinin A, enhances levels of alpha-2-macroglobulin in induced sputum of patients with mild asthma Source: Eur Respir J 2001; 18: Suppl. 33, 162s Year: 2001
DLCO change in systemic sclerosis patients after prostaglandin E1 infusion: preliminary data Source: Eur Respir J 2001; 18: Suppl. 33, 219s Year: 2001
The influence of antileukotriene therapy with montelukast (M) on thromboxane B2 /leukotriene E4 (TXB2 /LTE4 ) ratio in the urine of asthmatic subjects and other inflammatory markers Source: Eur Respir J 2003; 22: Suppl. 45, 102s Year: 2003
Serum level of VIP (vasoactive intestinal polypeptide) in patients with COPD in stable state and during exacerbation Source: Eur Respir J 2001; 18: Suppl. 33, 483s Year: 2001
COPD: Acute exacerbation (AE) rate and saturation in the patients with different plasma surfactant protein D (SP-D) level Source: Annual Congress 2013 –COPD mechanisms Year: 2013
High sensivity C reactive protein (HS-CRP) levels mark pulmonary and systemic inflammation in stable COPD Source: Eur Respir J 2006; 28: Suppl. 50, 337s Year: 2006
Vitamin c level in the serum of smokers and nonsmokers with COPD in stable state and during exacerbation Source: Annual Congress 2009 - COPD: exacerbation and clinical problems Year: 2009
Elevated serum inflammatory markers in patients with stable COPD Source: Annual Congress 2009 - Respiratory mechanics, tissue and cell dysfunction in pulmonary disease Year: 2009
The effects of inhaled steroids, leukotriene receptor antagonists and theophylline on induced sputum cell counts, serum and sputum ECP levels in mild persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001
Elevated serum IL-8: a biomarker indicating exacerbation-prone COPD Source: International Congress 2017 – COPD biomarkers Year: 2017
Urinary LTE4 (U-LTE4 ) level after systemic corticosteroid (CS) treatment Source: Eur Respir J 2004; 24: Suppl. 48, 132s Year: 2004
Reduced bone density in inhaled corticosteroids-treated asthmatic patients showing decreased cortisol response to low-dose ACTH test Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma Year: 2008
Prostaglandin D2 (PGD2 ) and tryptase release into blood after adenosine and methacholine challenges in asthmatic patients Source: Eur Respir J 2006; 28: Suppl. 50, 670s Year: 2006
A urine biomarker for severe obstructive sleep apnoea patients: lipocalin-type prostaglandin D synthase Source: Eur Respir J 2013; 42: 1563-1574 Year: 2013